TENX
Tenax Therapeutics, Inc.
$15.98
-1.57 (-8.95%)
At close · Jul 13
Market Cap
$423.87M
Shares
26,525,159
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$15.98
Open$17.12
Day$15.89–17.22
52W$5.77–19.40
Avg vol 30d1.3M
Short int1.8M · 6.7% float · 1.2d
Short vol30%
Last earningsNov 12, 2025
DataJan 2020–Jul 2026
Filing10-Q · May 12
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 17.2 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+37%
above
Price vs 50-day avg
+26%
above
RSI (14)
59
neutral
MACD trend
Positive
52-week position
75%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+49%
trailing
6-month return
0%
trailing
YTD return
+31%
this year
Relative strength
−10%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $13 › 200d $12 — 50d above 200d
Institutional flow
Accumulating
+67% holders QoQ · +34 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.74% of float · ▲ +132.9% MoM · 1.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
80 holders — near 2-yr high, broad support
Squeeze score
80
high risk · 0–100
Fundamentals
EPS growth
−17%
Y/Y
Free cash flow
$-35.8M
Balance sheet
$97.6M
net cash
Quant / Vol
risk profile
Volatility
74%
annualized · 1-yr
Max drawdown
−42%
past year
ATR
7.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+37%
Bullish
Price vs 50-day avg
+26%
Bullish
RSI (14)
59
Neutral
MACD trend
Positive
Bullish
52-week position
75%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $13 › 200d $12 — 50d above 200d
Institutional flow
Accumulating
+67% holders QoQ · +34 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.74% of float · ▲ +132.9% MoM · 1.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
80 holders — near 2-yr high, broad support
Price context
position in its 52-week range
52-wk low $6
Now $16 · 75%
52-wk high $19
vs 200-day avg +37%
vs 50-day avg +26%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TENX
this stock
Tenax Therapeutics, Inc.
|
$423.87M | +31.1% | -86.7% | — | 6.7% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.67B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TENX | -1.7% | +48.9% | -0.4% | +9.8% | +31.1% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -3.1% | +44.9% | -9.5% | +8.7% | +20.4% |